Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zinplava in multi-recurrent Clostridium difficile infection
NCT03880539Phase 4Completed
- Sponsor
- University of Kansas Medical Center
- Start
- Jun 2019
- Primary completion
- Nov 2021
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, open-label trial of bezlotoxumab in Clostridium difficile infection (CDI), sponsored by University of Kansas Medical Center. Primary endpoint: Clostridium difficile infection recurrence rate at 12 weeks. Started Jun 2019; status: completed.
02
Drugs
bezlotoxumab
03
Conditions
Clostridium difficile infection (CDI)
Beyond the preview
Go deeper on NCT03880539.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03880539.